Fundraising FoxFrazier Life Sciences — 2024 Investments
5 investments dated 2024 · listed companies and verified rows first · show all
Adverum is a clinical-stage gene therapy company developing Ixo-vec, an investigational single-administration intravitreal treatment for wet age-related macular degeneration and other ocular diseases, based on a proprietary adeno-associated virus (AAV) vector platform.
BiotechDeep TechHealthtechRedwood City, US
Thomas W. Chalberg(Executive Officer, Director)Steven D. Schwartz(Director)Mark S. Blumenkranz(Director)Linda Rubinstein(Executive Officer)Setareh Seyedkazemi(Executive Officer)Kishor Peter Soparkar(Executive Officer)
Co-investorsAvoro Capital Advisors5AM VenturesSamsara BioCapitalVenrock Healthcare Capital PartnersVivo Capital
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude Capital+9 more
.png)
Bluejay is a biotechnology company focused on therapeutic development.
BiotechSan Mateo, US
Keting Chu(Founder, Chief Executive Officer and Chairman of the Board)inDajun Yang(Director)Nancy Hong(Director)inAlon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
Co-investorsRA CapitalRiverVest Venture PartnersWellington ManagementFrazier Healthcare PartnersHBM Healthcare InvestmentsNovo Holdings+2 more
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsAlta PartnersCatalio Capital Management, LPDC Investment PartnersLongitude CapitalLongwood FundBiotechnology Value Fund+2 more
BiotechBoston, US
Darlene Deptula-Hicks(Executive Officer)inStephen S. Yoder(Executive Officer, Director)inDarlene M. Deptula-Hicks(Acting Chief Financial Officer)in
BoardChau Khuong(Director)inChristina Takke(Director)Steven Prelack(Director)
Co-investorsRidgeback CapitalBiotechnology Value FundOrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.